High blood pressure, or hypertension, is the main risk factor of cardiovascular disease and so two major therapeutic targets for treatment of hypertension are ACE and the AT1R. Although there are a number of anti-hypertensive drugs on the market such as ACE inhibitors (e.g., Captopril, Enalapril), and AT1R antagonists/blockers (e.g., Losartan, Valsartan) individual responses and side-effect profiles are highly variable, and often a mixed therapeutic regime is necessary. This evidence concerns the gene AGTR1 and cardiovascular disorder.